Slide 1: resTORbio and Adicet Bio
resTORbio and Adicet Bio June 23, 2020 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the expected structure, timing and completion of the proposed merger transaction, futur
Slide 3: Regulation M-A Legend
Regulation M-A Legend Important Additional Information About the Proposed Merger and Where to Find It This communication relates to the proposed merger transaction involving resTORbio, Inc. (“resTORbio”) and Adicet Bio, Inc. (“Adicet”) and may be deemed to be solicitation material in respect of the
Slide 4: Deal Rationale: About Adicet Bio
Deal Rationale: About Adicet Bio Developing off-the-shelf, engineered Gamma-Delta (γδ) CAR-T cell therapy pipeline for oncology and other indications Key anticipated advantages of Adicet’s γδ CAR-T cell therapy: Express T-cell and NK cell receptors, facilitating adaptive and innate anti-tumor immune
Slide 5: resTORbio/Adicet Bio Merger
resTORbio/Adicet Bio Merger Close expected 2H 2020 New company expected to be listed on NASDAQ (ticker TBD) Board of Directors expected to include five designated by Adicet + one from resTORbio + CEO On a pro forma basis, current Adicet equityholders are expected to own approximately 75% of the comb
Slide 6: Post Merger Leadership Team
Post Merger Leadership Team Chen Schor President and CEO Stewart Abbot, PhD Chief Scientific and Operating Officer Carrie Krehlik Chief Human Resource Officer Lloyd Klickstein, MD, PhD Chief Innovation Officer Francesco Galimi, MD, PhD Chief Medical Officer
Slide 7: Improving Cancer Immunotherapy
Improving Cancer Immunotherapy Presence of γδ T Cells Observed to Strongly Correlate with Positive Clinical Outcomes Meraviglia et al. 2017 Improved Disease Free Progression Colorectal Cancer γδ T cell hi γδ T cell lo γδ T cell lo / IFNγ lo Pan-Cancer: Improved Overall Prognosis Gentles et al. 2015
Slide 8: Building a Broad Pipeline of First in Class γδ CAR T Cell Therapy
Building a Broad Pipeline of First in Class γδ CAR T Cell Therapy NH: Non-Hodgkin’s ; HCC: hepatocellular carcinoma Program Target Indication Discovery Preclinical IND Phase 1 Phase 2 ADI-001 CD20 NH Lymphoma ADI-002 GPC3 HCC ADI-00x Undisclosed Solid Tumors ADI-00x Multiple Solid and Heme
Slide 9: Adicet Strategic Priorities
Adicet Strategic Priorities File IND for ADI-001 CD20 gamma-delta CAR-T Initiate Phase 1 clinical study in non-Hodgkin’s lymphoma File IND for ADI-002 GPC3 gamma-delta CAR-T Initiate Phase 1 in hepatocellular carcinoma Expand pipeline in oncology and other diseases Achieve milestones from collaborat
Slide 10: ADI-001: Allogeneic (CD20-CAR-γδ T Cell)
ADI-001: Allogeneic (CD20-CAR-γδ T Cell)
Slide 11: Large-Scale Manufacture of γδ T Cells
Large-Scale Manufacture of γδ T Cells Simplify for Robustness, Partner for Capability and Capacity Leukopheresis from a qualified donor Activate desired subsets of γδ T cells Engineer γδ T cells with CARs Expand ICP Cell Bank of final “Off the Shelf” ICP Treatment of multiple patients Production Pro
Slide 12: Key Anticipated Advantages of Adicet's Allogeneic γδ T Cell Platform
Key Anticipated Advantages of Adicet’s Allogeneic γδ T Cell Platform Innate and adaptive immunity imparted by TCR and NK receptors May mitigate tumor relapse MHC-independent tumor targeting Off-the-shelf product, potential to re-dose No / low potential to cause GvHD Potent IFNγ production Potential
Slide 13: Anticipated Differentiation From Other Allogeneic CAR-T Therapies
Anticipated Differentiation From Other Allogeneic CAR-T Therapies Allogeneic CAR-T Therapy Attributes Allogeneic CAR αβ T Cells Allogeneic CAR γδ T Cells Activity Recognize and bind tumor Predominantly CAR-mediated CAR and innate receptors Effectively kill tumor Predominantly CAR-CD8 αβ T subset All
Slide 14: CD20 CAR γδ T Cells Effectively Control Aggressive Lymphoma Tumors in Mice
CD20 CAR γδ T Cells Effectively Control Aggressive Lymphoma Tumors in Mice† Untreated animals succumb to highly aggressive tumors within 3 weeks 2nd generation (employing two co-stimulation domains) CD20 CAR γδ T cells effectively control multiple disseminated (iv) and localized (sc) tumors γδ T cel
Slide 15: CD20 γδ CAR-T Cells Effectively Control Repeat Lymphoma Challenges
CD20 γδ CAR-T Cells Effectively Control Repeat Lymphoma Challenges Repeat tumor challenge is one of the most stringent tests of anti-tumor activity CD20 CAR γδ T cell treatment initiated* when tumor volume ≥ 200mm3 Excellent tumor control in all animals at day 55 Secondary tumor challenge at day 60
Slide 16: CD20 CAR γδ T Cells Proliferate in Response to Activation in Tumors
CD20 CAR γδ T Cells Proliferate in Response to Activation in Tumors Substantial and specific target-mediated proliferation of CD20 CAR γδ T cells in localized lymphoma tumors at 6 days post treatment † Blood Spleen Liver Bone marrow Tumor Cell Number T cell Proliferation Day 2 Post-treatment CAR-T γ
Slide 17: Absence of GvHD with CD20 CAR γδ T Cells
Intravenous Raji Tumor in SRG-15 Mice† Absence of GvHD with CD20 CAR γδ T Cells No GvHD observed in mice treated with γδ T cells γδ T cells not expected to induce GvHD in clinical study No gene editing required to overcome GvHD with γδ T cells αβ CAR-T cell group succumbed to GvHD αβ CART cells CAR
Slide 18: Clinical Development Plan of ADI-001
Clinical Development Plan of ADI-001 Phase 1 study design NHL patients relapsing from 2 or more prior lines of treatment ~3 cohorts for dose escalation/safety Up to 50 patients at the selected dose Single treatment with ADI-001 Option for retreatment in select patients Pivotal study likely in DLBCL
Slide 19: ADI-001 Status
ADI-001 Status Pre-IND meeting completed IND application enabling activities in process ADI-001 IND application preparation in process Proposed ADI-001 clinical trial design well received by key centers and KOLs Preparations for ADI-001 Phase 1 Clinical study underway
Slide 20: Additional Pipeline in Solid Tumors: ADI-002
Additional Pipeline in Solid Tumors: ADI-002
Slide 21: Anticipated Advantages of Adicet's γδ CAR-T Cell Therapy in Solid Tumors
Anticipated Advantages of Adicet’s γδ CAR-T Cell Therapy in Solid Tumors Solid Tumor Therapy Goal Adicet γδ CAR-T Cell Anticipated Advantage Avoiding autologous cell exhaustion / dysfunction Healthy CMV-negative donor derived product preserves Vδ1 proliferative capacity Potential for >30 population
Slide 22: ADI-002: GPC3 Highly Expressed on Solid Tumors
ADI-002: GPC3 is highly expressed on a broad range of solid tumors, with limited expression levels on normal tissues Baumhoer et al., Am J Clin Pathol 2008;129:899-906 Ho et al., PLoS ONE 2012; 7: e37159 IHC Detection of GPC3 in human HCC vs normal liver Adicet Bio Confidential Tumor Non-tumor
Slide 23: Dose Dependent Anti-Tumor Effect of Vδ1 CAR-T Cells in Liver Cancer Model
Dose Dependent Anti-Tumor Effect of Vδ1 CAR-T Cells with GPC3-Targeting sIL15 CAR γδ1 T Cells in Liver Cancer Model † GPC3-targeting chimeric antigen receptor construct also encodes secretion of IL15 Single dose CAR γδ T cell treatment was initiated* when tumor volumes reached ~200mm3 Excellent CAR
Slide 24: Anticipated Advantage of ADI-002 in HCC
Anticipated Advantage of ADI-002 in HCC Potential to address low target tumor densities CAR-dependent and CAR-independent tumor targeting Optimizing γδ T cells to overcome tumor microenvironment-mediated immunosuppression Enhancing persistence of CAR-γδ T cells Favorable preclinical results Opportun
Slide 25: TCR-L Platform: Intracellular Solid Tumor Targets
TCR-L Platform: Intracellular Solid Tumor Targets
Slide 26: TCR-L Platform: CAR-T Using Intracellular Solid Tumor Targets
TCR-L Platform: CAR-T Using Intracellular Solid Tumor Targets Challenge Lack of disease-specific cell surface targets in solid tumors (80% of proteins are intracellular) TCR-L Proposed Solution Ability to target disease-specific intracellular proteins via peptide MHC complexes highly expands the tar
Slide 27: Deal Rationale: About Adicet Bio
Deal Rationale: About Adicet Bio Developing off-the-shelf, engineered Gamma-Delta (γδ) CAR-T cell therapy pipeline for oncology and other indications Key anticipated advantages of Adicet’s γδ CAR-T cell therapy: Express T-cell and NK cell receptors, facilitating adaptive and innate anti-tumor immune
Slide 28: Backup Slides
resTORDbio | Adicet Bio Backup Slides
Slide 29: CD20 CAR γδ T Cells Potently Kill Multiple Lymphoma Cell Lines in vitro
CD20 CAR γδ T Cells Potently Kill Multiple Lymphoma Cell Lines in vitro † Potent activity against tumors expressing high and low levels of CD20 Potent activity against tumors expressing HLA-Class 1 or HLA-Class 1 null CD20 CAR potentiates initial innate tumor recognition and killing Will-2 cells wer
Slide 30: Adicet: Leader in CAR & TCR Engineered γδ1 T cells
Adicet: Leader in CAR & TCR Engineered γδ1 T cells Adicet is a leader in the development of CAR-modified healthy donor-derived γδ1 T cell therapies Source: Adapted from Immuno-Oncology Technology 1 (2019) 3–10 Company T-cell type Source Gadeta αβ Blood GammaDelta Therapeutics γδ1 Skin/Blood TC Bioph
Slide 31: Anticipated Differentiation From Bispecific Antibody T cell Recruitment
Anticipated Differentiation From Bispecific Antibody T cell Recruitment for Tumor Immunotherapy *Adicet’s γδ T cell products are predominantly Vδ1 cells Attribute Bispecific Antibodies Allogeneic CART γδ T Cells Potency Requires “healthy” patient T cells Yes No Tumor recognition by multiple receptor
Slide 32: Bispecific Antibodies vs Allogeneic CART γδ T Cells
*Adicet’s γδ T cell products are predominantly Vδ1 cells Attribute Bispecific Antibodies Allogeneic CART γδ T Cells Potency MHC-unrestricted tumor recognition Yes Yes Inhibitory and activating receptor expression Balanced Predominantly activating Tumor-induced secretion of multiple cytokines Limited
Slide 33: Intellectual Property Portfolio
Intellectual Property Portfolio Composition of matter for CAR constructs, TCRL constructs, engineered γδ T cells products ADI-001 exclusivity in the US expected to expire in 2038 (not taking into account H-W extension) Antigen binding domains directed to certain targets Reagents, related protocols a
Slide 34: Regeneron Collaboration
Regeneron Collaboration In conjunction with Regeneron, Adicet discovers and develops γδ T cells engineered with CARs and TCRs Adicet has the right to use certain of Regeneron’s proprietary mice Five-year research collaboration signed July 2016 Adicet has the right to develop and commercialize the fi
Slide 35: Adicet's Key Anticipated Differentiation From γδ T cell Competitors
Adicet’s Key Anticipated Differentiation From γδ T cell Competitors Robust and practical proprietary antibody-based manufacturing method for γδ T cells Unique ability to selectively expand multiple γδ T cell subpopulations Large-scale expansion of blood-derived γδ T cells Production of highly potent
Slide 36: CAR-T Cell Therapy Journey
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 CAR-T Cell Therapy Journey 2015 Adicet Bio Founded ~2017 Yescarta approved by US FDA for r/r DLBCL 2012 U. Penn CART19 assets acquired by Novartis 2017 Kite Pharma acquired for $11.9B 2013 Juno Therapeutics founded 2009 Kite Pharm
Slide 37: About Adicet Bio
About Adicet Bio Founded in 2015 with $44M Series A financing Completed $80M Series B financing in September 2019 Developing off-the-shelf, engineered allogeneic γδ T cell therapy for oncology indications and other diseases cGMP-compliant manufacturing from healthy donors Proprietary intracellular t
Slide 38: RTB101: Potent TORC1 inhibitor
RTB101: Potent Target of rapamycin complex 1 (TORC1) inhibitor
Slide 39: RTB101 and CVR
RTB101 Expect to continue the development of RTB101 for a COVID-19 related indication, with clinical data expected by Q1 2021. The terms of the merger agreement contemplate that a contingent value right (a “CVR”) will be distributed to resTORbio stockholders as of the effective time of the merger, e